Review
Oncology
Jake Drobner, Alain Kaldany, Mihir S. Shah, Saum Ghodoussipour
Summary: This review aims to evaluate the role of salvage radical prostatectomy in patients with prostate cancer recurrence after initial radiotherapy. Radical prostatectomy has shown oncologic benefits but also carries the risk of functional complications. There is no consensus on the optimal salvage approach for localized prostate cancer recurrence, but the review suggests that salvage radical prostatectomy can offer meaningful cancer control for select patients with radiation-resistant disease.
Article
Oncology
Derya Tilki, Ming-Hui Chen, Jing Wu, Hartwig Huland, Markus Graefen, Osama Mohamad, Janet E. Cowan, Felix Y. Feng, Peter R. Carroll, Anthony V. D'Amico
Summary: A study found that initiating salvage radiation therapy (sRT) after prostate-specific antigen (PSA) failure above a PSA level of 0.25 ng/mL is associated with an increased risk of all-cause mortality (ACM) among patients with at most one high-risk factor.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Marnix J. A. Rasing, Max Peters, Marieke van Son, Marinus A. Moerland, Wietse Eppinga, Sandrine M. G. van de Pol, Juus Noteboom, Jan Lagendijk, Jochem R. N. van der Voort vanZyp
Summary: The purpose of this study was to investigate the recurrence characteristics in patients treated with focal salvage HDR brachytherapy. The results showed that after 19 Gy HDR brachytherapy, subsequent recurrences were mainly local and in-field.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Oncology
Mario Terlizzi, Elaine Johanna Limkin, Yasmina Moukasse, Pierre Blanchard
Summary: The management of patients with biochemical recurrence after prostatectomy has changed significantly in recent years. Close monitoring of prostate-specific antigen (PSA) and early salvage radiotherapy (RT) have become the standard of care. However, uncertainties remain regarding the management of high-risk patients and the role of imaging.
Article
Urology & Nephrology
Pierre-Gilles Vestris, Anthony Giwerc, Christophe Hennequin, Annabelle Goujon, Paul Meria, Jerome Verine, Francois Desgrandchamps, Eric de Kerviler, Pierre Mongiat-Artus, Alexandra Masson-Lecomte
Summary: The study retrospectively analyzed the perioperative and oncological outcomes of salvage cryotherapy in 29 patients with locally recurrent prostate cancer after radiation therapy. The results indicated that salvage focal cryotherapy may delay the initiation of ADT and provide an alternative treatment option for eligible patients, with acceptable perioperative morbidity and midterm oncological outcomes.
UROLOGIA INTERNATIONALIS
(2021)
Article
Urology & Nephrology
Armando Stabile, Rafael Sanchez-Salas, Rafael Tourinho-Barbosa, Petr Macek, Francesco Pellegrino, Giorgio Gandaglia, Marco Moschini, Nathalie Cathala, Annick Mombet, Francesco Montorsi, Alberto Briganti, Xavier Cathelineau
Summary: The location of prostate cancer does not significantly affect the oncologic outcomes after focal therapy, and the presence of an apical lesion should not be considered an exclusion criteria for focal therapy. Both HIFU and cryotherapy likely achieve similar medium-term oncologic results regardless of the location of prostate cancer.
JOURNAL OF UROLOGY
(2021)
Review
Urology & Nephrology
Nicholas G. Zaorsky, Jeremie Calais, Stefano Fanti, Derya Tilki, Tanya Dorff, Daniel E. Spratt, Amar U. Kishan
Summary: Biochemical recurrence after radical prostatectomy is common in intermediate-risk and high-risk prostate cancer patients. The optimal management includes a comprehensive evaluation with novel techniques like PET imaging and genomic analysis, along with consideration of traditional clinical variables. Salvage radiotherapy is the only known curative intervention for these patients without metastatic disease, but the importance of accurate timing, radiation dose, and systemic therapy must be emphasized.
NATURE REVIEWS UROLOGY
(2021)
Article
Oncology
Nicolas Giraud, Xavier Buy, Nam-Son Vuong, Richard Gaston, Anne-Laure Cazeau, Vittorio Catena, Jean Palussiere, Guilhem Roubaud, Paul Sargos
Summary: In-field oligo-recurrent prostate cancer after pelvic radiotherapy presents a challenging situation, where focal ablative treatment has shown to be a feasible option that may delay the initiation or modification of systemic treatment.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Mohammad Abufaraj, Abdelmuez Siyam, Mustafa Rami Ali, Rodrigo Suarez-Ibarrola, Lin Yang, Beat Foerster, Shahrokh F. Shariat
Summary: Local salvage therapies for radiation recurrent prostate cancer can lead to impaired urinary and sexual functions, but the likelihood of these sequalae may be predictable based on the patient's pre-salvage general health status. Despite the adverse consequences, the use of local salvage therapies may be justified for local disease control, but decision-making should involve informed patient input in a shared process.
Review
Surgery
Arnas Rakauskas, Giancarlo Marra, Isabel Heidegger, Veeru Kasivisvanathan, Alexander Kretschmer, Fabio Zattoni, Felix Preisser, Derya Tilki, Igor Tsaur, Roderick van den Bergh, Claudia Kesch, Francesco Ceci, Christian Fankhauser, Giorgio Gandaglia, Massimo Valerio
Summary: Focal therapy is a modern approach that selectively treats specific parts of the prostate, aiming to retain oncological benefits while minimizing side effects. It has shown to significantly reduce adverse events and preserve genito-urinary function compared to whole gland treatments.
FRONTIERS IN SURGERY
(2021)
Article
Endocrinology & Metabolism
Sriram Deivasigamani, Hazem Orabi, Ahmed El-Shafei, Eric S. Adams, Srinath Kotamarti, Ali Aminsharifi, Leah Davis, Yuan Wu, J. Stephen Jones, Thomas J. Polascik
Summary: In this retrospective cohort study, it was found that salvage cryotherapy (SCT) following recurrence of prostate cancer (PCa) had similar oncological and functional outcomes compared to salvage treatment after brachytherapy (BT-SCT). These findings suggest that SCT can be a viable treatment option for local PCa recurrence following either BT or cryoablation failure.
Article
Urology & Nephrology
Luigi A. M. J. G. van Riel, Bart Geboers, Ertunc Kabaktepe, Alexander Blazevski, Daan J. Reesink, Pascal Stijns, Phillip D. Stricker, Juan Casanova, Jose Luis Dominguez-Escrig, Theo M. de Reijke, Matthijs J. Scheltema, Jorg R. Oddens
Summary: This study evaluated the safety, feasibility, and medium-term oncological and functional outcomes of salvage radical prostatectomy (sRP) for recurrent localized prostate cancer (PCa) following initial focal therapy using irreversible electroporation (IRE). The results showed that sRP is safe and feasible for these patients, with similar oncological and functional outcomes compared to primary RP. Strict patient selection for focal therapy and standardized follow-up are necessary.
Review
Urology & Nephrology
Giancarlo Marra, Alessandro Marquis, Takafumi Yanagisawa, Shahrokh F. Shariat, Karim Touijer, Paolo Gontero
Summary: A systematic review of salvage radical prostatectomy (sRP) revealed improved oncological and functional outcomes as well as reduced morbidity over recent years. Postoperative continence was preserved in 40.4% of patients, erectile function in <16%, and high-grade complications were described in 6.6% of patients. Despite remaining significant compared to primary radical prostatectomy, sRP shows durable oncological control and continuous improvement in morbidity.
EUROPEAN UROLOGY FOCUS
(2023)
Review
Urology & Nephrology
Luca F. Valle, Eric J. Lehrer, Daniela Markovic, David Elashoff, Rebecca Levin-Epstein, R. Jeffery Karnes, Robert E. Reiter, Matthew Rettig, Jeremie Calais, Nicholas G. Nickols, Robert T. Dess, Daniel E. Spratt, Michael L. Steinberg, Paul L. Nguyen, Brian J. Davis, Nicholas G. Zaorsky, Amar U. Kishan
Summary: In the management of locally recurrent prostate cancer after definitive radiotherapy, salvage treatment modalities show similar 5-yr recurrence-free survival rates compared to RP, but reirradiation may result in lower toxicity.
Article
Urology & Nephrology
Alexander Light, Max Peters, Deepika Reddy, Abi Kanthabalan, Marjorie Otieno, Menelaos Pavlou, Rumana Omar, Sola Adeleke, Francesco Giganti, Chris Brew-Graves, Norman R. Williams, Amr Emara, Athar Haroon, Arash Latifoltojar, Harbir Sidhu, Alex Freeman, Clement Orczyk, Ashok Nikapota, Tim Dudderidge, Richard G. Hindley, Jaspal Virdi, Manit Arya, Heather Payne, Anita V. Mitra, Jamshed Bomanji, Mathias Winkler, Gail Horan, Caroline Moore, Mark Emberton, Shonit Punwani, Hashim U. Ahmed, Taimur T. Shah
Summary: This study externally validated a model predicting failure of salvage focal ablation within 2 years in men with localised radiorecurrent prostate cancer. The model showed modest discrimination but good calibration and clinical utility. It could be used to improve treatment selection for salvage focal ablation. Rating: 8/10
Review
Oncology
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Angela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno
Summary: Cholangiocarcinomas are a heterogeneous group of tumors with distinct genomic alterations. Next-generation sequencing is a powerful tool for identifying gene variants and guiding personalized treatment for patients with cholangiocarcinomas. Understanding the use of NGS in molecular profiling is crucial for healthcare professionals to optimize treatment outcomes.
CANCER TREATMENT REVIEWS
(2024)